Isomorphic Labs in Advanced Talks to Raise $2 Billion Led by Thrive Capital

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, is in advanced discussions to raise more than $2 billion in a new funding round led by Thrive Capital, with Alphabet also participating. The round follows a $600 million Series A in 2025. CEO Demis Hassabis recently delayed the company's first clinical trials from late 2025 to late 2026, and the new capital provides runway to meet that revised target. Isomorphic was built on the scientific foundation of AlphaFold and has partnerships with Novartis, Eli Lilly, and Johnson & Johnson.